J-Pharma Co., Ltd.
Research J-Pharma Co., Ltd. (520A.T) on Bullrun: market cap JPY 7.28B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker520A.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyJPY
- Market capJPY 7.28B
- Financial periodFY2025
- RevenueJPY 0
- Net income-JPY 1.50B
- Free cash flow-JPY 1.70B
Valuation Snapshot
latest market cap is JPY 7.28B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | JPY 0 | -JPY 1.50B | -JPY 1.70B | n/a | n/a | JPY 2.30B | n/a | JPY 2.38B |
| FY2024 | JPY 0 | -JPY 1.65B | -JPY 1.42B | n/a | -92.67 | JPY 1.07B | n/a | JPY 950.12M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 7.28B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 JPY.
About J-Pharma Co., Ltd.
J-Pharma Co., Ltd. is engaged in the research and development of pharmaceutical drugs in Japan. The company researches and develops drugs targeting solute carrier (SLC) transporters, with emphasis on the LAT1 amino acid transporter. It is developing several compounds for various medical indications, including nanvuranlat (JPH203), a novel small-molecule compound identified as a selective inhibitor of LAT1 and provide treatment for biliary tract cancer, as well as for colorectal cancer;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is J-Pharma Co., Ltd.'s market cap?
J-Pharma Co., Ltd.'s market capitalization is JPY 7.28B.
What does J-Pharma Co., Ltd. do?
J-Pharma Co., Ltd. is engaged in the research and development of pharmaceutical drugs in Japan. The company researches and develops drugs targeting solute carrier (SLC) transporters, with emphasis on the LAT1 amino acid transporter.